Enabling robust assessment of QTc prolongation in early phase clinical trials. | Pharm Stat;16(3): 218-227, 2017 05. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Enabling robust assessment of QTc prolongation in early phase clinical trials.

Mehrotra, Devan V; Fan, Li; Liu, Fang; Tsai, Kuenhi.

Affiliation

Mehrotra DV; Merck & Co., Inc., North Wales, PA, USA.
Fan L; Merck & Co., Inc., North Wales, PA, USA.
Liu F; Merck & Co., Inc., North Wales, PA, USA.
Tsai K; Merck & Co., Inc., North Wales, PA, USA.

Pharm Stat ; 16(3): 218-227, 2017 05.

Article in En | MEDLINE | ID: mdl-28374497

Subject(s)
Key words

ICH E14; QT interval; electrocardiogram; exposure-response; mixed effects model

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Pharm Stat Journal subject: FARMACOLOGIA Year: 2017 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Pharm Stat Journal subject: FARMACOLOGIA Year: 2017 Document type: Article Affiliation country: Country of publication: